Clin Psychopharmacol Neurosci.  2021 Feb;19(1):174-178. 10.9758/cpn.2021.19.1.174.

Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases

Affiliations
  • 1National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini,” Teramo, Italy
  • 2Department of Neurosciences and Imaging, Chair of Psychiatry, University “G. d’Annunzio,” Chieti, Italy
  • 3School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
  • 4Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine “Federico II,” Naples, Italy
  • 5National Health Service, Department of Mental Health, Pescara, Italy
  • 6National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Cuneo, Italy

Abstract

Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2 /D3 receptors with preferential binding to the D 3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.

Keyword

Cariprazine; Clozapine; Effectiveness; Efficacy; Schizophrenia; Tolerability
Full Text Links
  • CPN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr